Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Tumor mutational burden (TMB) may be a promising predictive biomarker of response to PD-1/PD-L1 targeting in MSI-H colorectal cancer.
Authors
Marwan Fakih
City of Hope, Duarte, CA
Marwan Fakih, Jaideep Singh Sandhu, Ching Ouyang, Ethan Sokol, Jeffrey S. Ross, Vincent A. Miller, Dean Lim, Joseph Chao, Daniel V.T. Catenacci, May Thet Cho, Fadi S. Braiteh, Steven Brad Maron, Leah Chase, Samuel Jacob Klempner, Siraj Mahamed Ali, Alexa Betzig Schrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Biomarkers and Inflammatory Signatures
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 43)
DOI
10.1200/JCO.2019.37.8_suppl.43
Abstract #
43
Poster Bd #
B7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Pembrolizumab (Pem) in metastatic castration-resistant prostate cancer (mCRPC): Experience from a comprehensive cancer center.
First Author: Arya Mariam Roy
Poster
2024 ASCO Annual Meeting
Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma.
First Author: Mark Chang
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2023 ASCO Annual Meeting
ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.
First Author: Richard F. Riedel